Copayment level, treatment persistence, and healthcare utilization in hypertension patients treated with single-pill combination therapy

Journal of Medical Economics

Volumn 14, Issue 3, 2011, Pages 267-278

  Yang, Weiyi ^a,b   Kahler, Kristijan H ^a,b   Fellers, Thomas ^a,b   Orloff, John ^a,b   Chang, Joanne ^a,b   Bensimon, Arielle G ^a,b   Wu, Eric Q ^a,b   Fan, Chun Po Steve ^a,b   Yu, Andrew P ^a,b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b ANALYSIS GROUP   (United States)

Author keywords

Combination drug therapy; Copayment; Healthcare costs; Hospitalization; Hypertension; Medication persistence

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; MOEXIPRIL; OLMESARTAN; QUINAPRIL; TELMISARTAN; VALSARTAN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CORRELATION ANALYSIS; COST CONTROL; DATA BASE; DRUG COST; DRUG FORMULATION; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PILL; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; COST SHARING; DRUG COMBINATIONS; FEMALE; HEALTH SERVICES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MODELS, STATISTICAL; ODDS RATIO; PATIENT COMPLIANCE;

EID: 79956105623     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.570401     Document Type: Article

References (32)

1. Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003;290:891-7 (Pubitemid 37430460)
2. American Heart Association. Heart Disease & Stroke Statistics: 2009 Update At-a-Glance. Dallas, TX: American Heart Association, 2009. Available at: http://www.americanheart.org/downloadable/heart/1240250946756LS- 1982%20Heart%20and%20Stroke%20Update.042009.pdf [Last accessed July 25 2010]
3. Degli Esposti L, Valpiani G. Pharmacoeconomic burden of undertreating hypertension. Pharmacoeconomics 2004;22:907-28 (Pubitemid 39382185)
4. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427-31 (Pubitemid 36776153)
5. Neutel JM. Prescribing patterns in hypertension: the emerging role of fixed dose combinations for attaining BP goals in hypertensive patients. Curr Med Res Opin 2008;24:2389-401
6. Chobanian AV, Bakris GL, Black HR, et al. The National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. U.S. Department of Health and Human Services, National Institute of Health. Available at: http://www.nhlbi.nih.gov/ guidelines/hypertension/jnc7full.pdf [Last accessed 12 July 2010]
7. Chrysant SG. Using fixed-dose combination therapies to achieve blood pressure goals. Clin Drug Investig 2008;28:713-34
8. Gu Q, Paulose-Ram R, Dillon C, et al. Antihypertensive medication use among US adults with hypertension. Circulation 2006;113:213-21
9. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006;19:1190-6 (Pubitemid 44633590)
10. DiMatteo MR, Giordani PJ, Lepper HS, et al. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002;40:794-811
11. Ruilope LM, Burnier M, Muszbek N, et al. Public health value of fixed-dose combinations in hypertension. Blood Press 2008;17:5-14
12. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents. A meta-analysis. Hypertension 2010;55:399-407
13. Hess G, Hill J, Lau H, et al. Medication utilization patterns and hypertensionrelated expenditures among patients who were switched from fixed-dose to free-combination antihypertensive therapy. PT 2008;33:652-66
14. Yang W, Chang J, Kahler KH, et al. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin 2010;26:2065-76
15. Taira DA, Wong KS, Frech-Tamas F, et al. Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care. Am J Manag Care 2006;12:678-83 (Pubitemid 44748394)
16. Briesacher BA, Limcangco MR, Frech-Tamas F. New-user persistence with antihypertensives and prescription drug cost-sharing. J Clin Hypertens 2007;9:831-6
17. Maciejewski ML, Bryson CL, Perkins M, et al. Increasing copayments and adherence to diabetes, hypertension, and hyperlipidemic medications. Am J Manag Care 2010;16:e20-34
18. McCombs JS, Nichol MB, Newman CM, et al. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 1994;32:214-26
19. Perreault S, Dragomir A, Roy L, et al. Adherence level of antihypertensive agents in coronary artery disease. Br J Clin Pharmacol 2010;69:74-84
20. The Novartis Pharmacy Benefit Report: 2009/2010 Facts, Figures & Forecasts. Emigh R, ed. 17th edn. East Hanover, NJ: Novartis Pharmaceuticals Corporation
21. Breekveldt-Postma NS, Penning-van Beest FJ, Siiskonen SJ, et al. Effect of persistent use of antihypertensives on blood pressure goal attainment. Curr Med Res Opin 2008;24:1025-31 (Pubitemid 351579159)
22. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
23. Green PJ. Penalized likelihood for general semi-parametric regression models. Int Stat Rev 1987;55:245-59
24. Ruppert D, Wand MP, Carroll RJ. Semiparametric Regression. New York: Cambridge University Press
25. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000;9(9 Suppl):2-6
26. Nissinen A, Tuomilehto J. Evaluation of the antihypertensive effect of atenolol in fixed or free combination with chlorthalidone. Pharmatherapeutica 1980;2:462-8 (Pubitemid 11207055)
27. Asplund J, Danielson M, Ohman P. Patients compliance in hypertension - the importance of number of tablets. Br J Clin Pharmacol 1984;17:547-52 (Pubitemid 14057461)
28. Jackson 2nd KC, Sheng X, Nelson RE, et al. Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database. Clin Ther 2008;30:1558-63
29. Brixner DI, Jackson 2nd KC, Sheng X, et al. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free- and fixed-dose combinations. Curr Med Res Opin 2008;24:2597-607
30. Bramley TJ, Gerbino PP, Nightengale BS, et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006;12:239-45 (Pubitemid 47400613)
31. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-30 (Pubitemid 40847288)
32. Lynch WD, Markosyan K, Melkonian AK, et al. Effect of antihypertensive medication adherence among employees with hypertension. Am J Manag Care 2009;15:871-80